Acumen concentrated on developing investigational monoclonal antibody concentrating on amyloid beta oligomers
CHARLOTTESVILLE, Va. and CARMEL, Ind., April 27, 2022 (World NEWSWIRE) — Acumen Prescription drugs, Inc. (NASDAQ: ABOS), a clinical phase biopharmaceutical enterprise targeted on the enhancement of novel specific therapeutics for Alzheimer&CloseCurlyQuotes illness (Advertisement), nowadays introduced that Frontiers in Neuroscience printed a summary of preclinical proof supporting ACU193, a monoclonal antibody that selectively targets toxic soluble Aß oligomers (AßOs) for the potential remedy of early Alzheimer&CloseCurlyQuotes sickness. The write-up is titled “ACU193: An immunotherapeutic poised to exam the amyloid ß oligomer speculation of Alzheimer&CloseCurlyQuotes illness&CloseCurlyDoubleQuote and can be accessed below.
Research suggest that AßO-mediated neuronal toxicity is directly dependable for Alzheimer&CloseCurlyQuotes-affiliated memory and cognitive challenges. AßOs have been found to interact inside synapses of brain cells named neurons, which leads to altered neuronal function, and may initiate and perpetuate the approach of neurodegeneration, finally main to mobile dying.
“We are progressively mastering much more about the distinct roles particular entities in the amyloid cascade, like AßOs, enjoy in Alzheimer&CloseCurlyQuotes sickness pathology,&CloseCurlyDoubleQuote reported Eric Siemers, M.D., Chief Professional medical Officer at Acumen Pharmaceuticals and co-creator of the publication. “We consider focusing on AßOs continues to be a promising solution because evidence suggests they are the most toxic variety of Aß and may be dependable for the memory impairment and cognitive drop in Alzheimer&CloseCurlyQuotes patients. We expect our ongoing Phase I scientific trial of ACU193 to present further more explanatory data and evidence of system knowledge that will perhaps pave the way in direction of testing of this hypothesis in bigger research. We search ahead to sharing the effects from our Phase I medical demo at the time offered.&CloseCurlyDoubleQuote
Acumen thinks ACU193 has a lot of necessary qualities needed for a effective therapeutic and selectively binds to AßOs. Preclinical info highlights in the publication on ACU193 incorporate:
- ACU193 selectively binds AßOs with 650-fold selectivity in comparison to Aß monomers with restricted to no binding to fibrillar Aß in vitro
- ACU193 stops AßO-induced disruption of long-time period potentiation (LTP), a system of strengthening synapses that is important for discovering and memory
- ACU193 can bind to a broad variety of AßOs with various molecular weights
- The father or mother of ACU193, termed ACU3B3, stops AßO-induced disruption of calcium homeostasis, an early indicator of cellular dysfunction
- ACU3B3 considerably enhanced behavioral deficits across different assessments when administered to animal versions at an age when AßO ranges have been measurable but prior to plaque deposition
Current therapeutics focusing on amyloid plaque result in amyloid similar imaging abnormalities (ARIA), such as cerebral edema (ARIA-E) or microhemorrhage (ARIA-H), which could complicate the utility of this sort of medicines. Present preclinical details suggest that ACU193 is not envisioned to elicit ARIA side results because of to its significant selectivity for AßOs and confined binding to plaque.
About Acumen Prescription drugs, Inc.
Acumen, headquartered in Charlottesville, VA, with clinical functions based in Carmel, IN, is a clinical stage biopharmaceutical enterprise establishing a novel ailment-modifying method to treat Alzheimer&CloseCurlyQuotes condition. Acumen&CloseCurlyQuotes scientific founders pioneered analysis on AßOs, which a rising physique of evidence suggests are key triggers of Alzheimer&CloseCurlyQuotes illness pathology. Acumen is currently concentrated on advancing its investigational immunotherapy drug, ACU193, a humanized monoclonal antibody that selectively targets poisonous AßOs in INTERCEPT-Advertisement, a Stage I clinical trial involving early Alzheimer&CloseCurlyQuotes disease people. For additional information, take a look at www.acumenpharm.com.
Ahead-Wanting Statements
This press launch incorporates ahead&dashlooking statements within just the this means of The Non-public Securities Litigation Reform Act of 1995. Any statement describing Acumen&CloseCurlyQuotes aims, expectations, economical or other projections, intentions or beliefs is a ahead&dashlooking statement and need to be deemed an at&dashrisk assertion. Words and phrases these types of as “believes,&CloseCurlyDoubleQuote “expects,&CloseCurlyDoubleQuote “anticipates,&CloseCurlyDoubleQuote “could,&CloseCurlyDoubleQuote “would,&CloseCurlyDoubleQuote “seeks,&CloseCurlyDoubleQuote “aims,&CloseCurlyDoubleQuote “plans,&CloseCurlyDoubleQuote “potential,&CloseCurlyDoubleQuote “will&CloseCurlyDoubleQuote and comparable expressions are intended to detect forward&dashlooking statements, while not all ahead&dashlooking statements incorporate these figuring out text. Ahead&dashlooking statements involve statements regarding Acumen&CloseCurlyQuotes small business and the therapeutic possible of Acumen&CloseCurlyQuotes products candidate, ACU193, like its potential for improved security and efficacy as compared to other monoclonal antibodies in growth, as nicely as the expectations regarding the INTERCEPT&dashAD demo and expectations with respect to the position of AßOs in the possible cure of Alzheimer&CloseCurlyQuotes disorder. These statements are primarily based on the current beliefs and expectations of Acumen administration, and are issue to particular factors, hazards and uncertainties, specially individuals inherent in the process of exploring, creating and commercializing protected and effective human therapeutics. These types of challenges may possibly be amplified by the impacts of the COVID&dash19 pandemic. These and other challenges concerning Acumen&CloseCurlyQuotes programs are explained in added element in Acumen&CloseCurlyQuotes filings with the Securities and Exchange Commission (“SEC&CloseCurlyDoubleQuote), like in Acumen&CloseCurlyQuotes Yearly Report on Type 10&dashK for the 12 months ended December 31, 2021, filed with the SEC on March 28, 2021, which is offered on the SEC&CloseCurlyQuotes internet site at www.sec.gov. Copies of these and other documents are accessible from Acumen. Additional data will be produced accessible in other filings that Acumen tends to make from time to time with the SEC. These forward&dashlooking statements communicate only as of the day hereof, and Acumen expressly disclaims any obligation to update or revise any forward&dashlooking assertion, other than as if not demanded by legislation, no matter whether, as a consequence of new info, long term occasions or in any other case.
Contacts:
Media:
AcumenPR@westwicke.com
Traders:
investors@acumenpharm.com
